The use of polypills in cardiovascular disease management: Benefits vs challenges.
作者信息
Adil Yamaan, Siddiqui Shanezehra
机构信息
Dow University of Health Sciences, Karachi, Pakistan.
出版信息
Int J Cardiol Cardiovasc Risk Prev. 2024 Jul 16;22:200313. doi: 10.1016/j.ijcrp.2024.200313. eCollection 2024 Sep.
Abstract
摘要
相似文献
1
The use of polypills in cardiovascular disease management: Benefits vs challenges.复方制剂在心血管疾病管理中的应用：益处与挑战
Int J Cardiol Cardiovasc Risk Prev. 2024 Jul 16;22:200313. doi: 10.1016/j.ijcrp.2024.200313. eCollection 2024 Sep.
2
Inclusion of Polypills for Prevention of Cardiovascular Disease in the 23rd World Health Organization Model List of Essential Medicines: A Significant Step Towards Reducing Global Cardiovascular Morbidity and Mortality.将复方制剂纳入《世界卫生组织基本药物标准清单》第23版以预防心血管疾病：迈向降低全球心血管发病率和死亡率的重要一步。
Glob Heart. 2024 Feb 26;19(1):24. doi: 10.5334/gh.1310. eCollection 2024.
3
A review of polypills for the prevention of atherosclerotic cardiovascular disease.复方药丸预防动脉粥样硬化性心血管疾病的综述。
Am Heart J. 2023 Dec;266:74-85. doi: 10.1016/j.ahj.2023.08.012. Epub 2023 Aug 26.
4
Polypills for the prevention of Cardiovascular diseases.用于预防心血管疾病的复方制剂
Expert Opin Investig Drugs. 2016 Nov;25(11):1255-1264. doi: 10.1080/13543784.2016.1236912. Epub 2016 Sep 22.
5
Uses of polypills for cardiovascular disease and evidence to date.复方药物在心血管疾病中的应用及现有证据。
Lancet. 2017 Mar 11;389(10073):1055-1065. doi: 10.1016/S0140-6736(17)30553-6.
6
A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries.某些国家用于心血管疾病的复方药的可及性和可负担性调查。
Glob Heart. 2024 Jul 1;19(1):56. doi: 10.5334/gh.1335. eCollection 2024.
7
Barriers and Facilitators to the Use of Cardiovascular Fixed-Dose Combination Medication (Polypills) in Andhra Pradesh, India: A Mixed-Methods Study.印度安得拉邦使用心血管固定剂量复方药物（复方丸）的障碍和促进因素：一项混合方法研究。
Glob Heart. 2019 Sep;14(3):303-310. doi: 10.1016/j.gheart.2019.07.002.
8
Putting polypills into practice: challenges and lessons learned.将多效药丸付诸实践：挑战与经验教训。
Lancet. 2017 Mar 11;389(10073):1066-1074. doi: 10.1016/S0140-6736(17)30558-5.
9
The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials.“复方药丸”的疗效和耐受性：随机对照试验的荟萃分析。
PLoS One. 2012;7(12):e52145. doi: 10.1371/journal.pone.0052145. Epub 2012 Dec 19.
10
Polypills for primary prevention of cardiovascular disease.复方药丸用于心血管疾病的一级预防。
Nat Rev Cardiol. 2019 Oct;16(10):602-611. doi: 10.1038/s41569-019-0209-y.
本文引用的文献
1
Fixed Combination for the Treatment of Dyslipidaemia.固定剂量复方制剂治疗血脂异常。
Curr Atheroscler Rep. 2023 Oct;25(10):691-699. doi: 10.1007/s11883-023-01142-x. Epub 2023 Sep 16.
2
Polypill Strategy in Secondary Cardiovascular Prevention.复方药治疗在二级心血管预防中的应用。
N Engl J Med. 2022 Sep 15;387(11):967-977. doi: 10.1056/NEJMoa2208275. Epub 2022 Aug 26.
3
The feasibility of polypill for cardiovascular disease prevention in Asian Population.亚洲人群心血管疾病一级预防中使用复方药的可行性。
J Clin Hypertens (Greenwich). 2021 Mar;23(3):545-555. doi: 10.1111/jch.14075. Epub 2020 Oct 21.
4
Barriers and Facilitators to the Use of Cardiovascular Fixed-Dose Combination Medication (Polypills) in Andhra Pradesh, India: A Mixed-Methods Study.印度安得拉邦使用心血管固定剂量复方药物（复方丸）的障碍和促进因素：一项混合方法研究。
Glob Heart. 2019 Sep;14(3):303-310. doi: 10.1016/j.gheart.2019.07.002.
5
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.心血管疾病药物的可及性和可负担性及其对高收入、中等收入和低收入国家使用的影响：对 PURE 研究数据的分析。
Lancet. 2016 Jan 2;387(10013):61-9. doi: 10.1016/S0140-6736(15)00469-9. Epub 2015 Oct 20.
6
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.固定剂量联合策略对 CVD 患者或高危患者的依从性及相关风险因素的影响：UMPIRE 随机临床试验。
JAMA. 2013 Sep 4;310(9):918-29. doi: 10.1001/jama.2013.277064.
7
Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.联合治疗与单一疗法在降低血压方面的比较：对来自42项试验的11000名参与者的荟萃分析。
Am J Med. 2009 Mar;122(3):290-300. doi: 10.1016/j.amjmed.2008.09.038.
8
A strategy to reduce cardiovascular disease by more than 80%.一种将心血管疾病减少80%以上的策略。
BMJ. 2003 Jun 28;326(7404):1419. doi: 10.1136/bmj.326.7404.1419.
Zotero 插件